S A Messer - JoVE Visualize

Showing results (21-30 of 108) with videos related to

Pageof 11

Sort By:

Diagnostic Microbiology and Infectious Disease|October 29, 1998

Epidemiology of polyclonal gram-negative bacteremiaC Wendt, S A Messer, R J Hollis, et al.

Journal of Clinical Microbiology|April 12, 2003

Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001M A Pfaller, D J Diekema, S A Messer, et al.

Diagnostic Microbiology and Infectious Disease|May 6, 2003

In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICsM A Pfaller, S A Messer, L Boyken, et al.

The Journal of Pediatrics|November 1, 1996

Candida albicans arthritis one year after successful treatment of fungemia in a healthy infantH Swanson, P A Hughes, S A Messer, et al.

Diagnostic Microbiology and Infectious Disease|May 20, 2015

Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff valuesM A Pfaller, P R Rhomberg, S A Messer, et al.

Journal of Clinical Microbiology|October 4, 2000

Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar mediaM A Pfaller, S A Messer, A Houston, et al.

Journal of Clinical Microbiology|August 9, 2003

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungiD J Diekema, S A Messer, R J Hollis, et al.

Antimicrobial Agents and Chemotherapy|February 27, 2003

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolatesM A Pfaller, D J Diekema, S A Messer, et al.

Diagnostic Microbiology and Infectious Disease|April 29, 1998

National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of EpidemiologicM A Pfaller, R N Jones, S A Messer, et al.

Journal of Clinical Microbiology|March 8, 2003

In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICsJ B Pfaller, S A Messer, R J Hollis, et al.

Pageof 11

Showing results (21-30 of 108) with videos related to

Sort By:

Pageof 11

Diagnostic Microbiology and Infectious Disease|October 29, 1998

Epidemiology of polyclonal gram-negative bacteremiaC Wendt, S A Messer, R J Hollis, et al.

Journal of Clinical Microbiology|April 12, 2003

Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001M A Pfaller, D J Diekema, S A Messer, et al.

Diagnostic Microbiology and Infectious Disease|May 6, 2003

In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICsM A Pfaller, S A Messer, L Boyken, et al.

The Journal of Pediatrics|November 1, 1996

Candida albicans arthritis one year after successful treatment of fungemia in a healthy infantH Swanson, P A Hughes, S A Messer, et al.

Diagnostic Microbiology and Infectious Disease|May 20, 2015

Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff valuesM A Pfaller, P R Rhomberg, S A Messer, et al.

Journal of Clinical Microbiology|October 4, 2000

Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar mediaM A Pfaller, S A Messer, A Houston, et al.

Journal of Clinical Microbiology|August 9, 2003

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungiD J Diekema, S A Messer, R J Hollis, et al.

Antimicrobial Agents and Chemotherapy|February 27, 2003

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolatesM A Pfaller, D J Diekema, S A Messer, et al.

Diagnostic Microbiology and Infectious Disease|April 29, 1998

National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of EpidemiologicM A Pfaller, R N Jones, S A Messer, et al.

Journal of Clinical Microbiology|March 8, 2003

In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICsJ B Pfaller, S A Messer, R J Hollis, et al.

Pageof 11